• ILAE Main Picture
  • ILAE Main Picture
  • ILAE Main Picture
  • ILAE Main Picture
  • ILAE Main Picture
  • ILAE Main Picture
  • ILAE Main Picture
  • ILAE Main Picture
  • ILAE Main Picture
  • ILAE Main Picture
 Search search
 Contact Us

Ilae Facebook Ilae Twitter

View ILAE in:

Arabic  Arabic
Chinese  中文版
French  Français
German  Deutsch
Spanish  Español
Italian  Italiano
Japanese  日本語
Portugese  Português
Russian  Rусский


World Health Organization (WHO) and Epilepsy

The Executive Board of the World Health Organization has unanimously approved a strong resolution in support of improving epilepsy care and research.

The resolution – Global burden of epilepsy and the need for coordinated action at the country level to address its health, social and public knowledge implications – was formally sponsored by the People's Republic of China, the Russian Federation, the Maldives, Argentina, the Islamic Republic of Iran, Japan and Panama.

Next Step

The resolution will be presented at the WHO General Assembly in May for final approval. Once approved it will become a formal policy of the WHO so that the fight against epilepsy becomes a truly global effort.


World Health Organization - WHO

WHO programme on reducing the epilepsy treatment gap
WHO and Epilepsy

WHO video Epilepsy: Treat it, Defeat it

Please help this resolution succeed: Encourage your governments to support and co-sponsor the resolution at the WHO Assembly in May.

News from ILAE                                                                  All news

Epilepsy Awards Call for Nominations

Award deadline 1 March

Each year, the International League Against Epilepsy and the International Bureau For Epilepsy jointly bestow three prestigious awards: Ambassador for Epilepsy Awards, Social Accomplishment in Epilepsy Award and the Lifetime Achievement Award. These awards will be presented in September 2015 at the 31st International Epilepsy Congress, Istanbul 2015. ILAE and IBE member associations are now invited to submit nominations for these awards. The closing date for receipt of nominations for all three awards is March 1, 2015. Nomination Forms, Award rules and procedures and the list of previous recipients.

New! ILAE Leadership Development Program Scholarship
Application deadline 1 March, 2015

The ILAE is offering a Leadership Development Award to support the preparation and advancement of young physician leaders selected from ILAE chapters around the world. It affords a unique and exclusive opportunity to receive leadership development training, one-on-one guidance from a carefully selected mentor, and the opportunity to network with other rising leaders from around the globe. In 2015, its inaugural year, 15 candidates will be selected to participate in the program. More …

Caret imageMore news from ILAE

News Around the World                                                      All news

Innovative Medicines Initiative

Innovative Medicines Initiative (IMI)

Innovative Medicines Initiative (IMI) 2 has just launched its 3rd call for proposals. The first topic on the call is titled RADAR: Remote Assessment of Disease and Relapse programme, which is exploring ways to ensure that the healthcare system moves from a ‘diagnose and treat’ stance to a ‘predict and pre-empt’ approach. The first application will be in CNS and epilepsy is specifically mentioned. Submission deadline: 24 March, 2015.

Funding opportunities flyer | Call for proposals

Epilepsy Foundation Announces Shark Tank Competition<. Epilepsy Foundation

The Epilepsy Foundation is accepting entries in its 4th Annual Shark Tank competition, which seeks innovative ideas for epilepsy treatment and care. Finalists will present their ideas at the 2015 Antiepileptic Drug and Device Trials XIII, taking place May 13 to 15 in Aventura, Fla. The winner will receive up to $200,000 to advance his or her concept. Letters of intent for the contest must be received by Feb. 16.

WHO issues report: Global burden of epilepsy and the need for coordinated action at the country level to address its health, social and public knowledge implications

WHO Report on Epilepsy

Report addressing burden and impact; challenges and gaps in care; international context and the Secretariat's activities; and improving epilepsy care: what is needed.

Caret imageMore news around the world

Clinical Research News                                                        All news

IQ at 6 years after in utero exposure to antiepileptic drugs: A controlled cohort study

Researchers recruited children born to women with epilepsy (n = 243) and women without epilepsy (n = 287) during pregnancy and followed them prospectively to delineate the risk to child IQ associated with frequently prescribed antiepileptic drugs. Also see related editorial, "Fine-tuning risk assessment with antiepileptic drug use in pregnancy."

No evidence for human papillomavirus infection in focal cortical dysplasia IIb

The aetiology of Focal Cortical Dysplasia Type IIb (FCDIIb) remains enigmatic in patients suffering from drug-resistant epilepsy, and an aberrant activation of the mammalian target of rapamycin complex 1 signalling pathway (mTORC1) was detectedin this developmental brain malformation. Recently, the human papillomavirus (HPV) oncoprotein E6 has been identified as a potent activator of mTORC1. In this study, the authors tried to confirm two previous reports of HPV16 E6 infection using an independent series of 14 surgical specimens with histopathologically confirmed FCDIIb. (Annals of Neurology DOI: 10.1002/ana.24328)

Caret imageMore clinical research news

Basic Science of Epilepsy News                                           All news
Focus on Epilepsy in Nature Neuroscience

Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug

Caret image Summary for non-specialists

The authors of a recent study examined whether eslicarbazepine acetate (ESL) could target refractoriness to AEDs in addition to halting epileptogenesis. Using tissue resected from individuals with refractory epilepsy and pilocarpine- treated rodents, they found that ESL conferred use-dependent blockade of Na+ channels, hence alluding to its potential role in decreasing refractoriness. ESL was also found to block CaV3.2 calcium channels, mossy fiber sprouting and decrease neurodegeneration, hence having a likely beneficial role in slowing epileptogenesis. (Brain (2015) 138 (2): 371-387)

Adenosine kinase, glutamine synthetase and EAAT2 as gene therapy targets for temporal lobe epilepsy

Caret image Summary for non-specialists

Anti-epileptic drugs (AEDs) work only via a few known targets; the authors of a recent study investigated whether astrocytes could prove to be a potential avenue for novel AED discovery. Adeno-associated viral (AAV) vector was used to overexpress glutamine synthetase (GS) and excitatory amino-acid transporter 2 (EAAT2) to increase synaptic glutamate clearance. Additionally, microRNA technique was used to decrease expression of the enzyme adenosine kinase (ADK), and increase synaptic levels of adenosine – a naturally occurring anticonvulsant … more (Gene Therapy doi:10.1038/gt.2014.82)

Caret imageMore basic science news


Chapter Spotlight:

Liga Portuguesa Contra Epilepsia (LPCE)

The Liga Portuguesa Contra Epilepsia (LPCE) has been very active recently, sponsoring technical and scientific events and educational initiatives, as well as being active in health policy initiatives.

Caret image Read about the Portuguese League's activities


ILAE eNewsletter

Free monthly email newsletter with brief highights of the ILAE's activities.

To subscribe, please provide your email address:

Caret imageRead February issue



Definition of Epilepsy 2014 - New definition and commentaries.

Caret imageRead all guidelines


Home | Contact Us | Privacy & Security | Login | Sitemap

© 2015 International League Against Epilepsy